Clinical Trials and Advanced Development of Innovative Drug …

The new-drug pipeline is bursting with innovative treatments in clinical trials while the industry is growing by leaps and bounds. Many biotech stocks are catching the attention of Wall Street as new milestones and major developments are being achieved at a faster pace. The pipeline of new drugs of all kinds has exploded. According to, more than 1,480 drugs filed for Phase 3, or late-stage, trials with the U.S. Food and Drug Administration this year, and the FDA has more than 32,000 late-stage studies registered. The SPDR SP Biotech ETF (XBI) has gained over 45 percent in 2017 to its highest level in more than two years leaving a few industry experts to believe the climb isn’t over just yet for biotech leaders such as: Therapix Biosciences Ltd. (NASDAQ: TRPX), Medtronic plc (NYSE: MDT), Koninklijke Philips N.V. (NYSE: PHG), Teva Pharmaceuticals (NYSE:

... read more at: